SAN DIEGO / Apr 18, 2024 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring strategic alternatives to maximize stockholder value. Potential strategic alternatives that may be explored or evaluated... Read More

SAN DIEGO / Apr 01, 2024 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that effective March 27, 2024, the Compensation Committee of DermTech’s Board of Directors granted an aggregate of 26,240 restricted stock units to eight new employees under its 2022 Inducement Equity Incentive Plan, as... Read More

SAN DIEGO / Mar 08, 2024 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place March 8th-12th in San Diego, California. The first research abstract, “Non-invasive gene expression... Read More

Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 55 percent year-over-year Test revenue increased 38 percent versus the fourth quarter of 2022 Estimated cash runway into the first quarter of 2025 SAN DIEGO / Feb 29, 2024 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its... Read More

SAN DIEGO / Feb 13, 2024 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, will host a conference call and webcast on Thursday, February 29, 2024 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fourth-quarter 2023 operating and financial results. In advance of the call on February 29, 2024, DermTech will... Read More

- Ongoing emphasis on growing revenue for the DermTech Melanoma Test (DMT) - Approximately $40 million in total operating expense reductions compared to fiscal 2022 resulting from all restructuring actions SAN DIEGO / Jan 31, 2024 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced additional... Read More

Study demonstrated the DMT’s effectiveness as a melanoma rule-out test for all skin types Negative predictive value (NPV) higher than 99% regardless of skin type SAN DIEGO / Jan 18, 2024 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported positive topline results from a study evaluating the foundational... Read More

Trust 2 Study confirms negative predictive value (NPV) of 99.7% for the foundational gene expression assay Optional TERT promoter mutation testing does not significantly alter sensitivity, NPV or positive predictive value (PPV) SAN DIEGO / Jan 16, 2024 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today... Read More

Trust 2 Study demonstrated powerful clinical utility for the DMT as a rule-out test for melanoma Negative predictive value (NPV) higher than 99% SAN DIEGO / Jan 08, 2024 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported positive topline results from its Trust 2 Study, which evaluated the foundational... Read More

SAN DIEGO / Dec 14, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the grant to 15 new employees of restricted stock units representing the contingent right to receive up to an aggregate of 56,230 shares of the Company’s common stock under its 2022 Inducement Equity Incentive Plan, as... Read More

Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 24 percent year-over-year Test revenue increased 8 percent versus the third quarter of 2022 Cash runway into the first quarter of 2025 SAN DIEGO / Nov 02, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its third-quarter... Read More

SAN DIEGO / Oct 12, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, will host a conference call and webcast on Thursday, November 2, 2023 at 5:00 p.m. Eastern Time (ET) to discuss the Company's third-quarter 2023 operating and financial results. In advance of the call on November 2, 2023, DermTech will issue... Read More

SAN DIEGO / Sep 21, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that DermTech’s Compensation Committee has granted an equity award to its new chief commercial officer, Mark Aguillard. The award was granted pursuant to the terms of Mr. Aguillard’s employment letter and as a material... Read More

SAN DIEGO / Sep 19, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced agreements with Highmark Inc. (Highmark). The contracts, which are in addition to a favorable coverage policy, enhance access to the foundational assay of the DermTech Melanoma Test (DMT). Highmark and its Blue-branded... Read More

SAN DIEGO / Sep 11, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the appointment of Mark Aguillard as chief commercial officer effective September 19, 2023. Mr. Aguillard will lead DermTech’s overall commercial strategy and execution. Commenting on Mr. Aguillard’s appointment, Bret... Read More

SAN DIEGO / Aug 25, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the grant to six new employees of restricted stock units representing the contingent right to receive up to an aggregate of 24,720 shares of the Company’s common stock under its 2022 Inducement Equity Incentive Plan, as... Read More

Covered lives increased to 133 million Average selling price and test revenue grew sequentially Cash runway into the first quarter of 2025 SAN DIEGO / Aug 03, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its second-quarter 2023 financial results. “We’ve recently taken a few necessary steps... Read More

SAN DIEGO / Jul 19, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced a favorable coverage policy with a Blues plan in Michigan. The favorable coverage policy, which is in addition to a contract that became effective in August 2022, enhances access to the foundational assay of the DermTech... Read More

SAN DIEGO / Jul 17, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, will host a conference call and webcast on Thursday, August 3, 2023 at 5:00 p.m. Eastern Time (ET) to discuss the Company's second-quarter 2023 operating and financial results. In advance of the call on August 3, 2023, DermTech will issue its... Read More

SAN DIEGO / Jul 12, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced a favorable coverage policy from Highmark Inc. (Highmark). Highmark and its Blue-branded affiliates provide health insurance to approximately 7 million members in Pennsylvania, West Virginia, Delaware and New York. The... Read More

Strategic focus on growing revenue for the DermTech Melanoma Test (DMT) Annualized cost reduction of between $25 million and $30 million Cash runway extended into the first quarter of 2025 SAN DIEGO / Jun 28, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced restructuring actions that are... Read More

Health insurance plans and health systems use ECRI’s technology reviews to formulate coverage policies and clinical protocols SAN DIEGO / Jun 14, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that ECRI completed its evaluation of the Pigmented Lesion Assay (PLA), the foundational assay for... Read More

SAN DIEGO / Jun 07, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced an agreement with a Blues plan in Hawaii. The contract, which is in addition to a favorable coverage policy, enhances access to the foundational assay of the DermTech Melanoma Test (DMT) for the nearly 800,000 members of... Read More

SAN DIEGO / Jun 02, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the grant to eight new employees of restricted stock units representing the contingent right to receive up to an aggregate of 28,500 shares of the Company’s common stock under its 2022 Inducement Equity Incentive Plan, as... Read More

SAN DIEGO / May 31, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that the DermTech Melanoma Test (DMT) has tested more than 200,000 suspicious pigmented lesions. The DMT uses non-invasive Smart Stickers™ to test for select genomic markers associated with melanoma, one of the deadliest... Read More

SAN DIEGO / May 11, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced agreements with a Blues plan in South Carolina and the United Mine Workers of America Health and Retirement Funds (“UMWA Funds”). The contracts, which are both effective April 1, 2023, enhance access to the foundational... Read More

SAN DIEGO / May 10, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that its board of directors (“the board”) has granted an equity award to its new chief executive officer, Bret Christensen. The award was granted pursuant to the terms of Mr. Christensen’s employment letter and as a material... Read More

SAN DIEGO / May 09, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the appointment of Bret Christensen, previously chief commercial officer of Insulet, as president, chief executive officer and a member of the board of directors (the board). Mr. Christensen succeeds Dr. John Dobak, who... Read More

Covered lives increased to 126 million Cash runway through the third quarter of 2024 SAN DIEGO / May 04, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported its first-quarter 2023 financial results. “In the last few months, we had excellent overall progress with payers and strong execution by our... Read More

To elevate the importance of regular skin checks, DermTech announces its third annual #Stickit2Melanoma campaign for Melanoma Awareness Month LA JOLLA, Calif. / May 01, 2023 / Business Wire / DermTech , Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the release of new survey data in conjunction with the launch of its third... Read More

SAN DIEGO / Apr 26, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced an agreement with a physician-founded, member-focused and community-based not-for-profit health plan in New York. The contract, which is in addition to a favorable coverage policy that became effective April 15, 2023,... Read More

SAN DIEGO / Apr 13, 2023 / Business Wire / DermTech, Inc. ( NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, will host a conference call and webcast on Thursday, May 4, 2023 at 5:00 p.m. Eastern Time (ET) to discuss the Company's first-quarter 2023 operating and financial results. In advance of the call on May 4, 2023, DermTech will issue its... Read More

LA JOLLA, Calif. / Apr 11, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced an agreement with a Blues plan in North Carolina. The contract, which is in addition to a favorable coverage policy that became effective March 15, 2023, enhances access to the foundational assay of the DermTech... Read More

Only 19% of respondents wear sunscreen year-round; Sun Regrets campaign provides education on the most common skin cancers and risks SAN DIEGO / Apr 05, 2023 / Business Wire / In a new survey of 1,000 millennials and 1,000 Gen Xers, 75% of respondents said that while they are mindful of their sun exposure, only 19% wear... Read More

SAN DIEGO / Apr 03, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the grant to eight new employees of restricted stock units representing the contingent right to receive up to an aggregate of 40,510 shares of the Company’s common stock under its 2022 Inducement Equity Incentive Plan, as... Read More

LA JOLLA, Calif. / Mar 07, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced an agreement with a Blues plan in Arizona. The agreement makes the foundational assay of the DermTech Melanoma Test (DMT) available to the approximately 1.9 million members of this plan. The DMT is an innovative,... Read More

LA JOLLA, Calif. / Mar 03, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that management is scheduled to present at the following investor conferences during March 2023. TD Cowen 43rd Annual Health Care Conference, Boston – fireside chat on March 8, 2023 at 1:30 p.m. ET. Oppenheimer 33rd... Read More

LA JOLLA, Calif. / Feb 10, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, will host a conference call and webcast on Thursday, March 2, 2023 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fourth-quarter 2022 operating and financial results. In advance of the call on March 2, 2023, DermTech will... Read More

LA JOLLA, Calif. / Feb 09, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that U.S. General Services Administration has recommended the Company’s foundational assay included in the DermTech Melanoma Test (DMT) for coverage by the Veterans Health Administration (VHA). The VHA is the largest... Read More

LA JOLLA, Calif. / Jan 27, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the grant to four new employees of restricted stock units representing the contingent right to receive up to an aggregate of 44,669 shares of the Company’s common stock under its 2022 Inducement Equity Incentive Plan,... Read More

LA JOLLA, Calif. / Jan 23, 2023 / Business Wire / DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced favorable coverage policies from two commercial payers comprising a Blues plan in Hawaii and a physician-founded, member-focused and community-based not-for-profit health plan in New York. The coverage policies... Read More

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that the Defense Health Agency’s Lab Joint Working Group has recommended the Company’s foundational assay included in the DermTech Melanoma Test (DMT) for coverage by TRICARE. TRICARE is the health care program for uniformed service members, retirees and their... Read More

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced favorable coverage policies from four commercial payers including Blue Cross Blue Shield of North Carolina (BCBS NC), Blue Cross Blue Shield of South Carolina (BCBS SC), Blue Cross Blue Shield of Louisiana (BCBS LA) and Blue Cross Blue Shield of Kansas City (BCBS... Read More